Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 2928

Next Previous
X
Search
Drug Profile

TQB 2928

Alternative Names: TQB-2928

Latest Information Update: 23 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors; SIRPA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Osteosarcoma; Solid tumours

Most Recent Events

  • 05 Sep 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase Ib trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (IV, Infusion) in September 2024 (NCT06585059)
  • 31 Jul 2024 Chia Tai Tianqing Pharmaceutical terminates phase-I clinical trials in Solid tumours and Lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral), based on the current status of the same target research and the company's overall layout in the field of tumors(NCT06297642)
  • 24 May 2024 Phase-I clinical trials in Lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT06297642)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top